About inebilizumab
CD19-directed monoclonal antibody
Used for
- Treating neuromyelitis optica spectrum disorder in adults who are AQP4-antibody positive
- Treating immunoglobulin G4-related disease in adults
Usual adult dose
For neuromyelitis optica: 300 mg by intravenous infusion, repeated after 2 weeks, then every 6 months. For IgG4-related disease: 300 mg twice, 2 weeks apart, then every 6 months.
Common side effects
- Urinary tract infection
- Joint pain
- Infusion reactions
- Low levels of immunoglobulins
Important warnings
- Serious infections can occur; screen for hepatitis B and tuberculosis before treatment.
- Vaccinations should be reviewed before treatment; live vaccines are generally avoided during treatment.
- Monitor blood counts and immunoglobulin levels.
- Infusion reactions can be serious and require monitoring.
Pregnancy
May harm an unborn baby; effective contraception is recommended during treatment and for 6 months after the last dose.
Breastfeeding
It is not known whether inebilizumab passes into breast milk; discuss potential risks with a healthcare professional.
Interactions
- Other medicines that suppress the immune system may increase infection risk.
- Live vaccines may be unsafe during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.